GeNeuro

19 articles about GeNeuro

• GeNeuro and Verily Collaborate to Advance Long-COVID Research

  10/19/2023

  GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an Alphabet precision health technology company, to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein in SARS-CoV-2 infection.

• GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab

  11/16/2022

  GeNeuro announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic, as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubünden in Chur and the Centre Hospitalier du Valais Romand in Sion.

• 

  Highlighted by Amylyx, the ALS Space is Gaining Momentum

  9/9/2022

  There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.
• 

  Fighting Neurodegeneration by Targeting Fossil Viruses in DNA 

  5/19/2022

  GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19. 

• Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID

  12/13/2021

  GeNeuro announced that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health and that it will receive in this regard a grant of 6.7 million Swiss francs to co-fund a Phase 2 clinical trial to treat patients with long-standing COVID who exhibit severe neurological and psychiatric symptoms.

• GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID

  9/24/2021

  Research aims to confirm evidence of the expression of human endogenous retrovirus W envelope protein (HERV-W ENV or W-ENV) in long-haul COVID patients, and identify affected patients who may benefit from a treatment with GeNeuro’s temelimab.

• 

  Clinical Catch-Up: June 22-26

  6/29/2020

  It was a busy week for clinical trial updates. Here’s a look.
• 

  BioSpace Movers & Shakers, April 24

  4/24/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with this week's Movers & Shakers.

• GeNeuro And Servier Announce Six-Month Results From CHANGE-MS Phase IIb Study In Multiple Sclerosis

  8/28/2017

• GeNeuro Announces First Patient Treated In Phase IIa Study With Gnbac1 In Type 1 Diabetes

  6/19/2017

• GeNeuro Initiates Phase IIa Study With Gnbac1 In Type 1 Diabetes In Australia

  4/19/2017

• GeNeuro Signs CRADA Agreement With NIH To Develop Novel Antibody Treatment For ALS

  2/8/2017

• GeNeuro Announces First Patients Treated In Phase 2b Study For Multiple Sclerosis

  6/1/2016

• GeNeuro Announces First Patients Treated In Phase IIb Study For Multiple Sclerosis

  5/31/2016

• GeNeuro Announces The Launch Of Phase IIb Proof-Of-Concept Study With Gnbac1 In Multiple Sclerosis And Servier Equity Investment

  12/18/2015

• GeNeuro Appoints Dr. Gordon Francis And Giacomo Di Nepi To Board Of Directors

  5/5/2015

• GeNeuro, Servier Ink $455M MS Drug Pact

  12/2/2014

• GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis

  9/3/2014

• GeNeuro Successfully Completes Phase 2a Clinical Study With Novel Approach to Treat Multiple Sclerosis

  11/4/2013